FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4372333312> ?p ?o ?g. }

• W4372333312 abstract "Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting.A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting.All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs.Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi." @default.
• W4372333312 created "2023-05-07" @default.
• W4372333312 creator A5000564041 @default.
• W4372333312 creator A5005677068 @default.
• W4372333312 creator A5005829512 @default.
• W4372333312 creator A5009701108 @default.
• W4372333312 creator A5010940695 @default.
• W4372333312 creator A5012143202 @default.
• W4372333312 creator A5014223329 @default.
• W4372333312 creator A5016371744 @default.
• W4372333312 creator A5021185581 @default.
• W4372333312 creator A5022581320 @default.
• W4372333312 creator A5030622173 @default.
• W4372333312 creator A5031105664 @default.
• W4372333312 creator A5031211824 @default.
• W4372333312 creator A5032945961 @default.
• W4372333312 creator A5037844441 @default.
• W4372333312 creator A5037970330 @default.
• W4372333312 creator A5038204813 @default.
• W4372333312 creator A5039378096 @default.
• W4372333312 creator A5040120471 @default.
• W4372333312 creator A5045129075 @default.
• W4372333312 creator A5045605957 @default.
• W4372333312 creator A5046835489 @default.
• W4372333312 creator A5048782528 @default.
• W4372333312 creator A5052403208 @default.
• W4372333312 creator A5056621219 @default.
• W4372333312 creator A5057780132 @default.
• W4372333312 creator A5064502436 @default.
• W4372333312 creator A5064626077 @default.
• W4372333312 creator A5068562484 @default.
• W4372333312 creator A5072921779 @default.
• W4372333312 creator A5073719611 @default.
• W4372333312 creator A5077316526 @default.
• W4372333312 creator A5078464112 @default.
• W4372333312 creator A5080048082 @default.
• W4372333312 creator A5082073660 @default.
• W4372333312 creator A5083408516 @default.
• W4372333312 creator A5084027825 @default.
• W4372333312 creator A5085126287 @default.
• W4372333312 creator A5087986245 @default.
• W4372333312 creator A5089788519 @default.
• W4372333312 date "2023-05-04" @default.
• W4372333312 modified "2023-10-18" @default.
• W4372333312 title "Targeting homologous recombination deficiency in uterine leiomyosarcoma" @default.
• W4372333312 cites W1502045029 @default.
• W4372333312 cites W1605463263 @default.
• W4372333312 cites W1841331176 @default.
• W4372333312 cites W1979699797 @default.
• W4372333312 cites W2002401075 @default.
• W4372333312 cites W2014522837 @default.
• W4372333312 cites W2033816200 @default.
• W4372333312 cites W2036580730 @default.
• W4372333312 cites W2049524122 @default.
• W4372333312 cites W2087588809 @default.
• W4372333312 cites W2087949216 @default.
• W4372333312 cites W2096843793 @default.
• W4372333312 cites W2101519297 @default.
• W4372333312 cites W2106578986 @default.
• W4372333312 cites W2121419775 @default.
• W4372333312 cites W2122584762 @default.
• W4372333312 cites W2123575910 @default.
• W4372333312 cites W2128170579 @default.
• W4372333312 cites W2130078242 @default.
• W4372333312 cites W2137755195 @default.
• W4372333312 cites W2146271367 @default.
• W4372333312 cites W2152061559 @default.
• W4372333312 cites W2167564136 @default.
• W4372333312 cites W2172342370 @default.
• W4372333312 cites W2281514816 @default.
• W4372333312 cites W2387879652 @default.
• W4372333312 cites W2400204549 @default.
• W4372333312 cites W2405513305 @default.
• W4372333312 cites W2514437732 @default.
• W4372333312 cites W2560609004 @default.
• W4372333312 cites W2561855604 @default.
• W4372333312 cites W2588395027 @default.
• W4372333312 cites W2596164112 @default.
• W4372333312 cites W2606436364 @default.
• W4372333312 cites W2606495925 @default.
• W4372333312 cites W2737389832 @default.
• W4372333312 cites W2749641460 @default.
• W4372333312 cites W2754327139 @default.
• W4372333312 cites W2765468373 @default.
• W4372333312 cites W2766493195 @default.
• W4372333312 cites W2782477516 @default.
• W4372333312 cites W2789843538 @default.
• W4372333312 cites W2800002600 @default.
• W4372333312 cites W2803089592 @default.
• W4372333312 cites W2809584150 @default.
• W4372333312 cites W2884457322 @default.
• W4372333312 cites W2890641162 @default.
• W4372333312 cites W2892812402 @default.
• W4372333312 cites W2897430921 @default.
• W4372333312 cites W2901506506 @default.
• W4372333312 cites W2904093244 @default.
• W4372333312 cites W2951874439 @default.
• W4372333312 cites W2954262935 @default.
• W4372333312 cites W2975141952 @default.
• W4372333312 cites W2981548686 @default.

• next